This $1,234,505 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research by The General Hospital Corporation (Massachusetts General Hospital) to revolutionize antibody-drug conjugate therapy for refractory breast cancers by cotargeting the tumor microenvironment. The 3-year award, effective March 1, 2025, will enable the institution's specialized research facilities and expertise to advance this cutting-edge biomedical research. As a prominent academic medical center, Massachusetts General Hospital frequently partners with federal agencies like the NIH and Department of Defense on high-impact research initiatives across various disease areas.
Generated 3/4/25, 6:00 AM